Gastrointestinal Stromal Tumors
Idrx Inc. is focused on clinical research in metastatic and unresectable gastrointestinal stromal tumors (GIST), with work centered on advanced disease settings where treatment options remain limited.
- Metastatic GIST
- Unresectable GIST
- Antitumor activity
The sponsor’s active program in this area reflects a therapeutic interest in targeted oncology for difficult-to-treat sarcoma subtypes.
Early-Stage Oncology Development
The clinical portfolio includes first-in-human investigation of a novel oncology agent, with emphasis on establishing initial safety and activity in patients with advanced GIST.
- First-in-human study
- Safety and tolerability
- Clinical antitumor assessment
This area highlights interest in early translational development for new cancer therapies.
Cardiac Safety and QT Evaluation
Research activity also includes assessment of QT interval effects and QTcF relationships, supporting cardiac safety characterization for an investigational oncology treatment.
- QTcF analysis
- Cardiac repolarization
- Exposure-response evaluation
These investigations place emphasis on monitoring potential cardiovascular safety considerations during cancer drug development.
Multinational Clinical Research
The sponsor’s trial network spans multiple countries and collaborating sites, indicating an international research footprint supporting enrollment in advanced oncology studies.
- United States
- United Kingdom
- Belgium
- Spain
- Germany
Clinical activity across several regions supports access to patients with rare and aggressive gastrointestinal tumors.
